Experimental hyaline membrane disease in the premature monkey : effects of antenatal dexamethasone . 
<br>
<br> A blind , randomized trial of antenatal glucocorticoid treatment was conducted using the premature monkey ( Macaca nemestrina ) model of <font color="red">hyaline_2</font> <font color="red">membrane_2</font> <font color="red">disease_2</font> <font color="red">(_2</font> <font color="red">HMD_2</font> <font color="red">)_2</font> <font color="red">._2</font> Twelve dams received dexamethasone ( 2 mg / dose ) 72 , 48 , and 24 h before abdominal delivery at 135 + /- 1 days of gestation . Twelve control animals received saline . Infants of dexamethasone - treated dams had <font color="red">significantly_1</font> <font color="red">lower_1</font> <font color="red">incidence_2</font> <font color="red">and_2</font> <font color="red">severity_2</font> <font color="red">of_2</font> <font color="red">HMD_2</font> than did infants of control animals ( 50 versus 92% , p less than 0.05 ) . Improvement with treatment was markedly greater for males than for females . Differences in <font color="red">volume_2</font> <font color="red">-_2</font> <font color="red">pressure_2</font> <font color="red">behavior_2</font> <font color="red">of_1</font> <font color="red">the_1</font> <font color="red">excised_1</font> <font color="red">lungs_1</font> included greater <font color="red">distensibility_1</font> in the infants from dexamethasone - treated dams ( 20.6 + /- 7.1 ml / g dry lung versus 14.7 + /- 6.1 , p less than 0.05 ) and <font color="red">enhanced_1</font> <font color="red">deflation_2</font> <font color="red">stability_2</font> with treatment . Accelerated <font color="red">production_1</font> <font color="red">of_1</font> <font color="red">surface_1</font> <font color="red">active_1</font> <font color="red">material_1</font> <font color="red">(_1</font> <font color="red">SAM_1</font> <font color="red">)_1</font> <font color="red">phospholipids_1</font> in infants from dexamethasone - treated dams was indicated by increases in <font color="red">total_2</font> <font color="red">lung_3</font> <font color="red">phospholipid_3</font> ( 84.5 + /- 8.1 mg / g dry lung versus 75.1 + /- 9.9 , p less than 0.025 ) , <font color="red">alveolar_3</font> <font color="red">lavage_3</font> <font color="red">fluid_3</font> <font color="red">phospholipid_3</font> ( 5.65 + /- 3.33 mg / g dry lung versus 3.01 + /- 1.84 , p less than 0.05 ) , and <font color="red">alveolar_3</font> <font color="red">lavage_3</font> <font color="red">fluid_3</font> <font color="red">disaturated_3</font> <font color="red">phosphatidylcholine_3</font> <font color="red">(_2</font> <font color="red">DPC_2</font> <font color="red">)_2</font> ( 2.47 + /- 1.84 mg / g dry lung versus 1.06 + /- 1.05 , p less than 0.05 ) . <font color="red">Incorporation_1</font> <font color="red">of_1</font> <font color="red">14C_1</font> <font color="red">-_1</font> <font color="red">palmitate_1</font> <font color="red">into_1</font> <font color="red">lung_1</font> <font color="red">lipid_1</font> was not influenced by dexamethasone , but a significantly greater portion of the label appeared in the DPC fraction with treatment . Antenatal dexamethasone treatment was successful in reducing the <font color="red">incidence_1</font> <font color="red">and_1</font> <font color="red">severity_2</font> <font color="red">of_2</font> <font color="red">experimental_2</font> <font color="red">HMD_2</font> in this animal model ; the beneficial effects of treatment were associated with <font color="red">accelerated_1</font> <font color="red">maturation_2</font> <font color="red">of_2</font> <font color="red">fetal_2</font> <font color="red">pulmonary_2</font> <font color="red">functions_2</font> <font color="red">,_2</font> including , but not limited to , <font color="red">synthetic_2</font> <font color="red">metabolism_2</font> <font color="red">of_2</font> <font color="red">SAM_2</font> <font color="red">phospholipid_2</font> <font color="red">._2</font>